Dr Lior Shaltiel is an awarded executive and scientist with extensive multidisciplinary international experience, specializing in drug delivery systems. Lior is the CEO and Director at NurExone Biologic Inc., an Israeli owned biopharmaceutical company with 16 employees deploying cutting-edge exosome technologies to treat Spinal Cord Injury/CNS indications through an intranasal administration.
In 2015, Lior initiated and serves Academic Head of the BioMed-MBA program at the Hebrew University Business School (HUBS) to align academic knowledge with entrepreneurial success. Lior has extensive industry experience to capitalize upon investment opportunities and most recently was appointed as the Chairman of the MedTech division at the Israeli Association of Engineers.
